uniQure N.V. (NASDAQ:QURE) Short Interest Down 13.7% in March

uniQure N.V. (NASDAQ:QURE) was the target of a large decline in short interest in March. As of March 31st, there was short interest totaling 10,981,448 shares, a decline of 13.7% from the March 15th total of 12,718,685 shares. Approximately 18.4% of the shares of the stock are sold short. Based on an average daily trading volume, of 1,985,368 shares, the days-to-cover ratio is presently 5.5 days.

uniQure Stock Performance

NASDAQ:QURE opened at $17.58 on Friday. The business has a 50 day moving average of $17.67 and a 200 day moving average of $28.29. The company has a market capitalization of $1.10 billion, a price-to-earnings ratio of -5.10 and a beta of 0.75. uniQure has a 1-year low of $8.73 and a 1-year high of $71.50. The company has a debt-to-equity ratio of 0.25, a current ratio of 10.43 and a quick ratio of 10.43.

uniQure (NASDAQ:QURE) last released its earnings results on Tuesday, March 3rd. The biotechnology company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.93) by $0.37. The company had revenue of $5.57 million during the quarter, compared to the consensus estimate of $4.84 million. uniQure had a negative return on equity of 174.03% and a negative net margin of 1,236.00%. On average, sell-side analysts predict that uniQure will post -3.75 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Stifel Nicolaus set a $14.00 price objective on uniQure in a report on Monday, March 2nd. Barclays cut their price objective on uniQure from $31.00 to $25.00 and set an “equal weight” rating for the company in a report on Monday, March 23rd. Wall Street Zen raised shares of uniQure from a “sell” rating to a “hold” rating in a report on Saturday, March 28th. HC Wainwright reissued a “buy” rating and issued a $70.00 price target on shares of uniQure in a report on Tuesday, March 10th. Finally, Wells Fargo & Company raised shares of uniQure from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $15.00 to $60.00 in a report on Monday, March 9th. Ten analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, uniQure currently has an average rating of “Moderate Buy” and an average target price of $42.75.

Insider Buying and Selling at uniQure

In other uniQure news, CFO Christian Klemt sold 12,000 shares of uniQure stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total transaction of $108,720.00. Following the completion of the transaction, the chief financial officer owned 226,581 shares of the company’s stock, valued at $2,052,823.86. The trade was a 5.03% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Matthew C. Kapusta sold 14,581 shares of uniQure stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $9.06, for a total value of $132,103.86. Following the transaction, the chief executive officer directly owned 660,658 shares of the company’s stock, valued at $5,985,561.48. The trade was a 2.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 49,396 shares of company stock valued at $722,734 in the last quarter. 4.79% of the stock is currently owned by corporate insiders.

Institutional Trading of uniQure

A number of hedge funds have recently bought and sold shares of the company. Private Trust Co. NA bought a new stake in uniQure in the third quarter valued at approximately $28,000. Torren Management LLC bought a new stake in uniQure in the fourth quarter valued at approximately $28,000. Jones Financial Companies Lllp lifted its position in uniQure by 509.0% in the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 509 shares during the last quarter. IFP Advisors Inc bought a new stake in uniQure in the fourth quarter valued at approximately $48,000. Finally, Smartleaf Asset Management LLC bought a new stake in uniQure in the fourth quarter valued at approximately $48,000. Institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.